EGFR and neoplasm: The metalloprotease domain of ADAM9 can cleave the heparin-binding epidermal growth factor like growth factor (HB-EGF) precursor to yield soluble HB-EGF29, thereby activating epidermal growth factor receptor (EGFR) signal transduction to promote tumor growth and angiogenesis30.